Humana (NYSE:HUM) PT Raised to $350.00

Humana (NYSE:HUM) had its price objective upped by equities researchers at Citigroup from $340.00 to $350.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the insurance provider’s stock. Citigroup‘s price objective suggests a potential upside of 10.21% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Deutsche Bank assumed coverage on Humana in a research note on Thursday, September 12th. They issued a “hold” rating and a $300.00 target price for the company. Mizuho assumed coverage on Humana in a research note on Thursday, October 17th. They issued a “buy” rating and a $316.00 target price for the company. Morgan Stanley lowered their target price on Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a research note on Thursday, September 26th. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a research note on Friday. Finally, BMO Capital Markets cut Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $345.00 to $290.00 in a research note on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. Humana has an average rating of “Buy” and an average price target of $322.63.

Shares of NYSE HUM traded up $2.44 during midday trading on Thursday, hitting $317.58. The stock had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The company’s 50-day simple moving average is $277.48 and its 200 day simple moving average is $270.93. The firm has a market cap of $39.82 billion, a P/E ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. Humana has a fifty-two week low of $225.65 and a fifty-two week high of $342.03. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. The company had revenue of $16.24 billion during the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the firm earned $4.58 EPS. Equities analysts expect that Humana will post 17.75 EPS for the current fiscal year.

In other news, insider Brian P. Leclaire sold 7,239 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the transaction, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.54% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of HUM. Endurance Wealth Management Inc. boosted its position in shares of Humana by 354.5% in the 3rd quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock worth $26,000 after purchasing an additional 78 shares during the last quarter. Whittier Trust Co. bought a new position in Humana during the second quarter worth about $27,000. Next Capital Management LLC bought a new position in Humana during the second quarter worth about $27,000. Quest Capital Management Inc. ADV bought a new position in Humana during the third quarter worth about $30,000. Finally, Advantage Investment Management LLC lifted its holdings in Humana by 287.1% during the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 89 shares in the last quarter. Institutional investors and hedge funds own 92.93% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: How does the Beige Book influence monetary policy?

Stock Target Advisor

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.